Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07132242) titled 'SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Condition:
Metastatic Breast Cancer With HER2 Positive
Intervention:
Drug: SHR-A1811 4.0mg/kg
Drug: Pyrotinib 240mg
Drug: SHR-A1811 4.8mg/kg
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 30, 2025
Target Sample Size: 84
To...